ReviewExpert review of vaccines2016
Human papillomavirus vaccination in HIV-infected women: need for increased coverage.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.Systematic reviews · 2018Pooled it
- Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status.Journal of the International AIDS Society · 2018Pooled it
- Preliminary Impact of Public Health Messaging on HPV Vaccine Uptake Among Adolescent Girls and Young Women Living with HIV in Central Uganda.AIDS and behavior · 2026Trial
- Review
- Vaccination Coverage of People Living with HIV: Before and after Interventional Action.Vaccines · 2024Article
- Review
- Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Prognostic value of lncRNA HOXA-AS3 in cervical cancer by targeting miR-29a-3p and its regulatory effect on tumor progression.The journal of obstetrics and gynaecology research · 2022Article
- High-risk HPV positivity is a long-term risk factor for recurrence after cervical excision procedure in women living with HIV.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Article
- Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.EClinicalMedicine · 2020Article
- Cervical cancer risk in women living with HIV across four continents: A multicohort study.International journal of cancer · 2020Observational
- Risk Factors for Human Papillomavirus Infection and Abnormal Cervical Cytology Among Perinatally Human Immunodeficiency Virus-Infected and Uninfected Asian Youth.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Observational
- Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa.Southern African journal of HIV medicine · 2018Article
- Prevalence of HPV infection among HIV-positive and HIV-negative women in Central/Eastern Italy: Strategies of prevention.Oncology letters · 2017Article
- HIV-associated malignancies in children.Current opinion in HIV and AIDS · 2017Review
- Malignancies in women with HIV infection.Current opinion in HIV and AIDS · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Human immunodeficiency virus (HIV)-infected women carry a significant burden on human papillomavirus (HPV) infection and associated diseases. As HIV-infected individuals are living longer, the prevalence of HPV infection is rising and HPV-associated cytological abnormalities remain high despite successful treatments of HIV infection. Several HPV vaccines are currently available and recommended for adolescents and adults up to age 26. The vaccines are safe, immunogenic and effective in preventing diseases due to HPV types included in the vaccines, particularly among persons without prior HPV exposure. This review summarizes available data on the use of the HPV vaccines among HIV-infected women. The immunogenicity and safety of the vaccines are highlighted and in particular, barriers to vaccination among HIV-infected women are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.